Glaxo Seeks Guidance From Health Systems

The CEO shows intelligent moves by acknoledging that the pharmaceutical world is changing fast and taking new practical measures to meet  the new challenges. Showing close cooperation within the research group and placing the company ahead of your personnal interest can only have good effects on GSR. But, why mentionning outrageous figures about salaries in the days when abuse of capitalism...

Drug discovery driven by patient population, revenue outcome and government willingness to  buy the product

"He who pays the fiddler calls the tune."  Here's an example of the fiddler pro-actively asking the guy in the room with the deepest pocket what he'd like to hear.  If it's not something in the current repertoire, the fiddler seems willing to learn.  However, by the time he's got the new song by heart the guy with the deep pocket may have moved on to another venue.  Will...

Asking company investors and pharmaceutical users their opinions about the drugs that are needed seems like a logical approach to the needs for pharmaceutical drug development.  Hopefully, this unique analysis of company policy will be successful and lead to changes that would be successful to other pharmaceutical development companies.  

GSK is discussing drug development with European countries and not the US. Implications???

This article  is  of interest since it  deals with the problems plaguing major drug manufacturers, which in essence can be seen as a consequence  of declining  job satisfaction and creativity  among the investigators. The fundsamental reason behinf the´difficulty  may be oversized structure  of Glaxo and its competitors. A lDifferent approach would be ...